Novartis International AG
General Information
Identification Code: 91269481588-28
Website: [object Object]
Entity Form: Corporation
Registration Category: Companies & groups
Registration Date: 4/27/2009
Last Update: 3/20/2024
EP Accredited Number: 5
Mission & Interests
Goals: Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Borders and security
- Business and industry
- Competition
- Consumers
- Customs
- Digital economy and society
- Economy, finance and the euro
- Employment and social affairs
- Environment
- External relations
- Institutional affairs
- International co-operation and development
- Justice and fundamental rights
- Public health
- Regional policy
- Research and innovation
- Single market
- Taxation
- Trade
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: Antimicrobial resistance (AMR), ATMP Regulation, Big data, Biosimilars & generics, Clinical Trials Regulation, Data Protection Regulation, EU IP policy, EU Relative Efficacy Assessment (EU REA), EU research policy, EU trade policy, Health Systems Performance Assessment, Health Technology Assessment & Market Access, Industrial policy, IHI, Outcomes-based healthcare systems, Orphan Medicinal Products Regulation, Paediatric Regulation, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainable Development Goals, CS3D, General Pharmaceutical Legislation (GPL), Critical Medicines Act, EU Mercury Regulation
Communication Activities: European Parliament lunch meeting on health data and rare diseases
European Parliament exhibition on heart health
European Parliament German speaking round table on IP
French speaking stakeholder event on the GPL
European Health Summit - session on GPL
Expert briefing sessions on Cell and Gene Therapies and rare diseases
Publication of Neuroendocrine Tumour Policy Recommendations
Communication efforts around radiopharmaceuticals in EU pharmaceutical legislation
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Novartis International AGForum 1
Post Code: CH-4002
City: Basel
Country: SWITZERLAND
Phone: [object Object]
EU Office
Address: Rue Belliard 40
City: Brussels
Country: BELGIUM
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: We have calculated the estimate of annual costs related to activities covered by the register by adding our membership fees, event costs, consultancy fees together with facilities (rental charges) and personal costs.
Membership Information
Members10 Percent: 0
Members25 Percent: 7
Members50 Percent: 2
Members75 Percent: 0
Members: 9
Members F T E: 2.75
Info Members: In 2023, 2 associates in the Brussels office spent up to 50% on activities
falling within the scope of the register.
Seven associates at global and regional headquarters spent up to 25 % of their time on activities falling within the scope of the register.
Other associates involved on activities falling within the scope of the register spent less than 10% of their time on such activities.
Structure
Structure Type: Structure
Is Member Of: We do not have members
Organisation Members: British Chamber of Commerce
Business Europe Trial membership
ECPA
EFPIA - Pillar 3 IMI
EFPIA (Pillar 1+2)
EFPIA: Pillar 3 ICH
EFPIA Country engagement
EFPIA Campaign mode
Eucope (Membership)
Eucope Membership - Support to the incentive Steering Group
EuropaBio
EuropeanIssuers
Friends of Europe
Kangaroo
Medicines for Europe
Medicines for Europe Biosimilar Medicines
Medicines for Europe VAM
Science Business Membership
EUMatrix
GIRP
FH Europe Foundation
European Access Academy
European Brain Council
SMA Alliance on NBS
International Patient Organisation for Primary Immunodeficiencies (IPOPI)
EUCOPE TRANSFORM
EURORDIS
EPF 20th Anniversary Policy Event
EPF Annual Plan
EPF HTA Simulation Project
Cancer Patient Europe
EFPIA CVD Workstream
European Business Summit
EUCOPE ECGP Coalition
European Alliance for Personalised Medicine Sponsorship
Nuclear Medicine Europe (NMEU)
European Cancer Organisation (ECO)
SPARC
European Alliance for Access to Safe Medicines (EAASM)
European Kidney Health Alliance (EKHA)
International Agency for the Prevention of Blindness (IAPB)